`
`JANSSEN PHARMACEUTICALS, INC.
`and JANSSEN PHARMACEUTICA NV,
`
`Civil Action No. 18:734 (CCC)(MF)
`
`Plaintiffs,
`
`v.
`
`TEVA PHARMACEUTICALS USA,
`INC.,
`
`Defendant.
`
`STIPULATION AND ORDER REGARDING
`INFRINGEMENT OF CLAIMS 1-21 OF U.S. PATENT NO. 9,439,906
`
`WHEREAS, Defendant Teva Pharmaceuticals USA, Inc.
`
`WHEREAS, the ANDA contains a
`
`WHEREAS, Plaintiffs Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV
`
`§ 271(e)(2); and
`
`Proposed Generic Products within the United States or importing the same into the United States,
`
`during th
`
`-21 of
`
`to the extent each of the Asserted Claims is found valid,
`
`and challenges the validity of each of the Asserted Claims.
`
`Janssen Ex. 2006
`Mylan v. Janssen
`IPR2020-00440
`
`
`
`Case 2:18-cv-00734-CCC-MF Document 88 Filed 06/08/20 Page 2 of 3 PageID: 373
`
`NOW THEREFORE, IT IS HEREBY STIPULATED, AGREED AND ORDERED that:
`
`1.
`
`For the purposes of this Action only, Teva will not contest that the making, using,
`
`infringement of any valid Asserted Claim. Teva reserves all rights to contest the validity of the
`
`Asserted Claims.
`
`2.
`
`If the Court renders a decision that any of the Asserted Claims is not invalid, a
`
`judgment of infringement will be entered against Teva for any such Asserted Claim and an order
`
`pursuant to 35 U.S.C. § 271(e)(4)(A) will be entered. The parties reserve all rights to seek or
`
`oppose additional remedies.
`
`3.
`
`Teva reserves all rights to appeal any decision of this Court with respect to the
`
`validity of the Asserted Claims but will not appeal any decision with respect to infringement of
`
`the Asserted Claims.
`
`4.
`
`On the basis of this Stipulation, Janssen and Teva will not pursue discovery on
`
`on infringement and Teva will not serve any rebuttal report on noninfringement.
`
`Dated: May 30, 2019
`
`s/ Keith J. Miller
`
`Keith J. Miller
`Michael J. Gesualdo
`ROBINSON MILLER LLC
`One Newark Center, 19th Floor
`Newark, New Jersey 07102
`(973) 690-5400
`
`Barbara L. Mullin (admitted pro hac vice)
`
`Respectfully submitted,
`
`s/ Christine I. Gannon
`
`Christine I. Gannon
`William T. Walsh, Jr.
`
`LLP
`One Riverfront Plaza
`1037 Raymond Blvd., Suite 600
`Newark, NJ 07102
`(973) 757-1100
`
`2
`
`Janssen Ex. 2006
`Mylan v. Janssen
`IPR2020-00440
`
`
`
`Case 2:18-cv-00734-CCC-MF Document 88 Filed 06/08/20 Page 3 of 3 PageID: 374
`
`Aron R. Fischer (admitted pro hac vice)
`Zhiqiang Liu
`Jeffrey Hughes (admitted pro hac vice)
`PATTERSON BELKNAP WEBB
`& TYLER LLP
`1133 Avenue of the Americas
`New York, NY 10036
`(212) 336-2000
`
`Attorneys for Plaintiffs Janssen
`Pharmaceuticals, Inc. and Janssen
`Pharmaceutica NV
`
`Jeanna M. Wacker (admitted pro hac vice)
`Christopher T. Jagoe
`Mira A. Mulvaney (admitted pro hac vice)
`Gregory Springsted (admitted pro hac vice)
`KIRKLAND & ELLIS LLP
`601 Lexington Avenue
`New York, NY 10022
`(212) 446-4800
`
`Attorneys for Defendant
`Teva Pharmaceuticals USA, Inc.
`
`SO ORDERED: __________________________
`Hon. Claire C. Cecchi, U.S.D.J.
`
`
`
`Date: June 8, 2020
`
`3
`
`Janssen Ex. 2006
`Mylan v. Janssen
`IPR2020-00440
`
`